NASDAQ:GCTK GlucoTrack (GCTK) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free GCTK Stock Alerts $0.50 +0.01 (+2.04%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.47▼$0.5250-Day Range$0.31▼$0.9052-Week Range$0.13▼$0.99Volume67,682 shsAverage Volume274,509 shsMarket Capitalization$13.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get GlucoTrack alerts: Email Address GlucoTrack MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 8 Articles This WeekInsider TradingAcquiring Shares$230,000 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.87 out of 5 starsMedical Sector781st out of 921 stocksMedical Instruments & Supplies Industry2nd out of 3 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for GlucoTrack.Read more about GlucoTrack's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.44% of the float of GlucoTrack has been sold short.Short Interest Ratio / Days to CoverGlucoTrack has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlucoTrack has recently decreased by 28.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlucoTrack does not currently pay a dividend.Dividend GrowthGlucoTrack does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GCTK. Previous Next 2.3 News and Social Media Coverage News SentimentGlucoTrack has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for GlucoTrack this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for GCTK on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows1 people have added GlucoTrack to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlucoTrack insiders have bought more of their company's stock than they have sold. Specifically, they have bought $230,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.70% of the stock of GlucoTrack is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.92% of the stock of GlucoTrack is held by institutions.Read more about GlucoTrack's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GlucoTrack is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlucoTrack is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlucoTrack has a P/B Ratio of 50.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GlucoTrack's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About GlucoTrack Stock (NASDAQ:GCTK)GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.Read More GCTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GCTK Stock News HeadlinesApril 25, 2024 | insidertrades.comInsider Buying: GlucoTrack, Inc. (NASDAQ:GCTK) Director Purchases 182,540 Shares of StockMay 18 at 1:16 AM | americanbankingnews.comGlucoTrack Stock Scheduled to Reverse Split on Monday, May 20th (NASDAQ:GCTK)May 17 at 3:26 PM | msn.comGCTK Stock Earnings: GlucoTrack Reported Results for Q1 2024May 16 at 9:20 AM | finance.yahoo.comGLUCOTRACK’S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDYMay 16 at 8:30 AM | globenewswire.comGLUCOTRACK'S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDYMay 16 at 8:17 AM | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Announces Reverse Stock SplitMay 15, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES REVERSE STOCK SPLITMay 2, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATIONApril 26, 2024 | investing.comGlucoTrack director Drew Sycoff buys $230k in company sharesApril 26, 2024 | msn.comNasdaq Rises 0.5%; Tesla Shares Jump After Q1 ResultsApril 25, 2024 | msn.comGlucoTrack And 2 Other Stocks Under $1 Insiders Are BuyingApril 25, 2024 | finance.yahoo.comDirector and 10% Owner Drew Sycoff Acquires 182,540 Shares of GlucoTrack Inc (GCTK)April 22, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENTApril 17, 2024 | finance.yahoo.comGlucoTrack, Inc. (GCTK)April 16, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORINGApril 2, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORMarch 13, 2024 | nz.finance.yahoo.comUK mortgage arrears rise 50% amid high interest ratesMarch 12, 2024 | globenewswire.comGLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITYFebruary 27, 2024 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Selects Cirtec Medical As Manufacturer For Its Implantable Continuous Blood Glucose MonitorFebruary 27, 2024 | globenewswire.comGLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORFebruary 13, 2024 | msn.comGlucotrack names Luis Malavé board chairFebruary 13, 2024 | finance.yahoo.comGLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORSJanuary 3, 2024 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Announces Early Accuracy Data For Its Implantable Continuous Glucose MonitorJanuary 2, 2024 | msn.comGlucoTrack stock jumps 13% on preclinical update for glucose monitorJanuary 2, 2024 | finance.yahoo.comGLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITORSee More Headlines Receive GCTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/18/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolNASDAQ:GCTK CUSIPN/A CIK1506983 Webwww.glucotrack.com Phone(201) 842-7715Fax972-8675-7850Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-207.55% Return on Assets-151.03% Debt Debt-to-Equity Ratio0.52 Current Ratio1.31 Quick Ratio3.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book50.00Miscellaneous Outstanding Shares27,390,000Free Float22,020,000Market Cap$13.70 million OptionableNot Optionable Beta0.10 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Paul V. Goode Ph.D. (Age 55)Chief Executive Officer Comp: $225kMr. Mark Tapsak Ph.D. (Age 55)Vice President of Technology Comp: $165kMs. Drinda Benjamin (Age 48)Vice President of Marketing Mr. James P. Thrower Ph.D. (Age 54)Vice President of Engineering Comp: $230kMr. Avner Gal MBA (Age 70)MSc.EE, Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board Comp: $187.39kMr. David Malka BA (Age 59)Co-Founder Comp: $191.86kMr. James S. Cardwell (Age 63)Chief Financial Officer More ExecutivesKey CompetitorsNEXGELNASDAQ:NXGLMicrobot MedicalNASDAQ:MBOTSTRATA Skin SciencesNASDAQ:SSKNPetVivoNASDAQ:PETVMeihua International Medical TechnologiesNASDAQ:MHUAView All CompetitorsInsidersDrew SycoffBought 182,540 shares on 4/22/2024Total: $230,000.40 ($1.26/share)View All Insider Transactions GCTK Stock Analysis - Frequently Asked Questions How have GCTK shares performed in 2024? GlucoTrack's stock was trading at $0.2615 at the start of the year. Since then, GCTK stock has increased by 91.2% and is now trading at $0.50. View the best growth stocks for 2024 here. When is GlucoTrack's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our GCTK earnings forecast. How were GlucoTrack's earnings last quarter? GlucoTrack, Inc. (NASDAQ:GCTK) released its earnings results on Thursday, March, 28th. The company reported ($0.10) earnings per share for the quarter. When did GlucoTrack's stock split? GlucoTrack's stock reverse split on Monday, May 20th 2024. The 1-5 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders will be adjusted after the market closes on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of GlucoTrack? Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GCTK) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
